Free Trial

Quest Diagnostics (NYSE:DGX) Given New $192.00 Price Target at Truist Financial

Quest Diagnostics logo with Medical background

Quest Diagnostics (NYSE:DGX - Get Free Report) had its price target lifted by equities research analysts at Truist Financial from $190.00 to $192.00 in a report issued on Wednesday,Benzinga reports. The brokerage presently has a "hold" rating on the medical research company's stock. Truist Financial's target price suggests a potential upside of 14.03% from the company's current price.

DGX has been the subject of several other research reports. Robert W. Baird boosted their price objective on Quest Diagnostics from $191.00 to $194.00 and gave the company an "outperform" rating in a report on Wednesday, April 23rd. Wall Street Zen cut Quest Diagnostics from a "buy" rating to a "hold" rating in a report on Saturday, June 7th. JPMorgan Chase & Co. upped their price target on Quest Diagnostics from $180.00 to $190.00 and gave the stock a "neutral" rating in a research note on Tuesday, May 6th. UBS Group dropped their target price on Quest Diagnostics from $176.00 to $175.00 and set a "neutral" rating on the stock in a report on Friday, July 18th. Finally, Evercore ISI increased their target price on Quest Diagnostics from $175.00 to $180.00 and gave the company an "in-line" rating in a report on Wednesday, April 23rd. Nine research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, Quest Diagnostics currently has a consensus rating of "Moderate Buy" and an average price target of $185.69.

Check Out Our Latest Research Report on DGX

Quest Diagnostics Stock Performance

Quest Diagnostics stock traded down $3.52 during mid-day trading on Wednesday, reaching $168.38. 1,877,511 shares of the stock traded hands, compared to its average volume of 1,283,198. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.09 and a quick ratio of 1.31. The business's 50-day moving average is $174.51 and its 200-day moving average is $169.61. The stock has a market capitalization of $18.83 billion, a PE ratio of 20.16, a price-to-earnings-growth ratio of 2.28 and a beta of 0.49. Quest Diagnostics has a 12-month low of $140.71 and a 12-month high of $182.38.

Quest Diagnostics (NYSE:DGX - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical research company reported $2.62 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.57 by $0.05. Quest Diagnostics had a return on equity of 15.24% and a net margin of 9.01%. The business had revenue of $2.76 billion during the quarter, compared to analyst estimates of $2.73 billion. During the same period last year, the company earned $2.35 EPS. The company's revenue for the quarter was up 15.2% on a year-over-year basis. As a group, sell-side analysts predict that Quest Diagnostics will post 9.7 EPS for the current fiscal year.

Insider Activity at Quest Diagnostics

In other news, SVP Mark E. Delaney sold 874 shares of Quest Diagnostics stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $175.72, for a total transaction of $153,579.28. Following the completion of the sale, the senior vice president owned 8,372 shares in the company, valued at $1,471,127.84. The trade was a 9.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 8.16% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the stock. Sequoia Financial Advisors LLC increased its holdings in shares of Quest Diagnostics by 4.9% in the second quarter. Sequoia Financial Advisors LLC now owns 22,052 shares of the medical research company's stock valued at $3,961,000 after purchasing an additional 1,022 shares during the last quarter. Yousif Capital Management LLC lifted its position in Quest Diagnostics by 23.6% during the second quarter. Yousif Capital Management LLC now owns 21,976 shares of the medical research company's stock worth $3,948,000 after purchasing an additional 4,195 shares during the period. MGO One Seven LLC lifted its position in Quest Diagnostics by 12.5% during the second quarter. MGO One Seven LLC now owns 7,043 shares of the medical research company's stock worth $1,265,000 after purchasing an additional 783 shares during the period. Allspring Global Investments Holdings LLC lifted its position in Quest Diagnostics by 14.9% during the second quarter. Allspring Global Investments Holdings LLC now owns 10,478 shares of the medical research company's stock worth $1,879,000 after purchasing an additional 1,362 shares during the period. Finally, CWM LLC lifted its position in Quest Diagnostics by 13.4% during the second quarter. CWM LLC now owns 23,853 shares of the medical research company's stock worth $4,285,000 after purchasing an additional 2,827 shares during the period. Institutional investors own 88.06% of the company's stock.

Quest Diagnostics Company Profile

(Get Free Report)

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States and internationally. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services.

Recommended Stories

Analyst Recommendations for Quest Diagnostics (NYSE:DGX)

Should You Invest $1,000 in Quest Diagnostics Right Now?

Before you consider Quest Diagnostics, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Quest Diagnostics wasn't on the list.

While Quest Diagnostics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

ACT FAST! Congress is Dumping these 3 Stocks
3 “Boring” Mega Cap Stocks to Turn Into Pure Profit
Joby vs. Archer: The $10 Billion eVTOL Battle

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines